Document 0347
 DOCN  M9550347
 TI    Loss of detectable antibody to hepatitis B surface antigen in immunized
       patients with hemophilia but without human immunodeficiency virus
       infection.
 DT    9505
 AU    Maris JM; Butler RB; Cohen AR; Division of Hematology, Children's
       Hospital of Philadelphia, PA; 19104.
 SO    J Pediatr. 1995 Feb;126(2):269-71. Unique Identifier : AIDSLINE
       MED/95147123
 AB    We investigated the loss of detectable antibody directed against the
       hepatitis B surface antigen after immunization with hepatitis B vaccine
       in 55 patients who were seronegative for the human immunodeficiency
       virus and had hemophilia. Twenty percent of patients lost detectable
       antibody at a mean of 4.6 years after completion of immunization.
       Monitoring of hepatitis B serostatus or routine revaccination may be
       necessary.
 DE    Child  Child, Preschool  Comparative Study  Hemophilia/*IMMUNOLOGY
       Hepatitis B Antibodies/*BLOOD  Hepatitis B Surface Antigens/*IMMUNOLOGY
       Hepatitis B Vaccines/*IMMUNOLOGY  Human  HIV Seronegativity/*IMMUNOLOGY
       HIV-1/*IMMUNOLOGY  Immunization  Infant  Philadelphia  Retrospective
       Studies  Time Factors  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).